Page last updated: 2024-11-01

nomifensine and Brain Damage, Chronic

nomifensine has been researched along with Brain Damage, Chronic in 1 studies

Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.

Brain Damage, Chronic: A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kondoh, T1
Lee, SH1
Low, WC1

Other Studies

1 other study available for nomifensine and Brain Damage, Chronic

ArticleYear
Alterations in striatal dopamine release and reuptake under conditions of mild, moderate, and severe cerebral ischemia.
    Neurosurgery, 1995, Volume: 37, Issue:5

    Topics: Animals; Brain Damage, Chronic; Brain Ischemia; Corpus Striatum; Dopamine; Dopamine Uptake Inhibitor

1995